Copyright © 2004 by the European Society of Cardiology.
Clinical research
Efficacy, safety and tolerability of ß-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure
a University of California, San Francisco School of Medicine, San Francisco, CA, USA
b University of Maryland, Baltimore, USA
c Cardiac Centers of Louisiana, Shreveport, Louisiana, USA
d Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg, Sweden
Received February 19, 2004;
revised April 23, 2004;
accepted May 6, 2004
* Corresponding author. Tel.: +46-31-342-2936; fax: +46-31-413447
E-mail address: john.wikstrand{at}wlab.gu.se
Aim To study the efficacy and tolerability of ß-blockade in elderly patients with heart failure in the MERIT-HF study.
Methods and results Cox proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI). Risk reduction was defined as (1-HR). In patients 
65 years total mortality was reduced by 37% (95% CI 17% to 52%; 
), sudden death by 43% (95% CI 17% to 61%; 
), and death from worsening heart failure by 61% (95% CI 32% to 77%; 
). Hospitalisations for worsening heart failure was reduced by 36% 
. Elderly patients with severe heart failure (NYHA class III/IV with ejection fraction 
0.25; 
, and patients above 75 years 
showed similar risk reductions. Metoprolol CR/XL was safe and well tolerated both during initiating therapy and during long-term follow-up.
Conclusions Metoprolol CR/XL was easily instituted, safe and well tolerated in elderly patients with systolic heart failure. The data suggest that these are the patients in whom treatment will have the greatest impact as shown by number of lives saved and number of hospitalisations avoided. The time has come to overcome the barriers that physicians perceive to ß-blocker treatment, and to provide it to the large number of elderly patients with heart failure in need of this therapy.
Key Words: Heart failure • ß-Blockade • Prognosis • Tolerability • Elderly
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Follath Beta-blockade today: the gap between evidence and practice Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Le Couteur, L. Bailey, and V. Naganathan Beta-blockers and heart failure in older people Eur. Heart J., April 1, 2006; 27(7): 887 - 888. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Burger and H. B.-L. Rocca Pharmacotherapy of Congestive Heart Failure in Elderly Patients Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 85 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Lehman Evidently... Evid. Based Med., February 1, 2005; 10(1): 8 - 8. [Full Text] [PDF]
|
|
|
|
|
|
Other articles noted Evid. Based Med., February 1, 2005; 10(1): 31 - 32. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Flather, M. C. Shibata, A. J.S. Coats, D. J. Van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, D. Dumitrascu, R. Ferrari, P. Lechat, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur. Heart J., February 1, 2005; 26(3): 215 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray Making sense of SENIORS Eur. Heart J., February 1, 2005; 26(3): 203 - 206. [Full Text] [PDF]
|
|